
Kwality Pharma Q2FY27: consolidated PAT jumps 106% YoY to ₹29 Cr, margins expand to 16%
Kwality Pharmaceuticals' consolidated Q2FY27 print was strong on both lines: revenue of ₹181.22 Cr grew 63.2% YoY (₹111.05 Cr) and 11.6% QoQ (₹162.35 Cr), while PAT of ₹29.03 Cr rose 105.6% YoY (₹14.12 Cr) and 13.3% QoQ (₹25.62 Cr) — figures from the audited P&L tables (standalone PAT ₹29.02 Cr, EPS ₹27.97, tracks consolidated almost exactly, confirming the African subsidiary's minimal contribution). No one-off items sat in either the current or year-ago quarter, so the growth is clean and organic rather than base-effect driven. Against management's own FY27 outlook — ₹700 Cr+ reaffirmed at the Q1 call — this print prompted a further guidance raise to ₹720 Cr+; H1FY27 revenue of ₹343.58 Cr now needs roughly ₹376 Cr in H2 to hit the new target, a bar the ~11-12% sequential pace of the last two quarters puts within reach, so the quarter reads as a beat against the company's own plan. Kwality carries no formal analyst coverage (confirmed via search and flagged in our pre-result preview), so there is no Street consensus to grade against; our own pre-print expectation of ₹180-190 Cr revenue was met at the low end on actual revenue of ₹181 Cr. Margins did the heavier lifting this quarter: EBITDA margin (OPM) expanded to ~27.5% from 22.8% YoY and 25.3% QoQ, and PAT margin to 15.95% from 12.6% YoY and 15.7% QoQ — both within or just above management's standing 26-27% EBITDA-margin band, which the MD&A attributes to improved operating leverage and a more favourable product mix. The quarter's corporate actions reinforce the regulated-market push behind that margin trend: EU-GMP certification from Hungary for the Cephalosporin and Oncology units (Nov 5) deepens access to high-value regulated markets, and the 4-acre Amritsar land purchase (Oct 19) for a new Unit 7 (4+ injectable lines, 6+ OSD lines) extends capacity toward the stated FY30 ambition of ₹1,500 Cr revenue. Working-capital discipline improved alongside the P&L, with debtor days down to 178 from 203 in FY26 and the cash-conversion cycle down to 130 days from 170 — supporting the cash generation needed to fund the capex ramp.
Key Highlights
- Consolidated revenue ₹181.22 Cr, +63.2% YoY (₹111.05 Cr) and +11.6% QoQ (₹162.35 Cr)
- Consolidated PAT ₹29.03 Cr, +105.6% YoY (₹14.12 Cr) and +13.3% QoQ (₹25.62 Cr); PAT margin 15.95% vs 12.61% YoY and 15.72% QoQ
- EBITDA margin (OPM) expanded to ~27.5% from 22.8% YoY and 25.3% QoQ on operating leverage and product mix
- Management raised FY27 revenue guidance to ₹720 Cr+ from the earlier ₹700 Cr+ target; EBITDA margin band of 26-27% unchanged
- H1FY27 consolidated revenue ₹343.58 Cr on sustained quarter-on-quarter momentum
- Received EU-GMP certification from Hungary for Cephalosporin and Oncology facilities (Nov 5, 2026), deepening regulated-market access
- Acquired 4 acres adjacent to Amritsar campus for Unit 7 (4+ injectable, 6+ OSD lines) to support long-term capacity
- Working capital improved: debtor days down to 178 (from 203 in FY26), cash conversion cycle down to 130 days (from 170)
Price Impact
More from KPL